Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 1/20 | 0.59 |
| ▸ | NOS2 | P35228 | 1/20 | 0.59 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.53 |
| ▸ | LOX | P28300 | 1/20 | 0.52 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.44 |
| ▸ | IDO1 | P14902 | 1/20 | 0.44 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.41 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.41 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CHKA | P35790 | 1/20 | 0.40 |
| ▸ | AR | P10275 | 1/20 | 0.40 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.38 |
| ▸ | KIF11 | P52732 | 1/20 | 0.38 |
| ▸ | AURKA | O14965 | 1/20 | 0.38 |
| ▸ | CES2 | O00748 | 1/20 | 0.38 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2609325 | 0.85 | NOS3 (0.53) | NOS3NOS2LOXL2LOXADRB1 | |
| SCHEMBL91323 | 0.85 | LOXL2 (0.48) | NOS3NOS2LOXL2LOXNOTUM | |
| SCHEMBL30636504 | 0.81 | SYK (0.47) | NOS3NOS2LOXL2LOXNOTUM | |
| SCHEMBL18745826 | 0.80 | LOXL2 (0.49) | NOS3NOS2LOXL2LOXNOTUM | |
| SCHEMBL20031366 | 0.78 | NOS3 (0.47) | NOS3NOS2LOXL2LOXADRB1 | |
| SCHEMBL20402487 | 0.78 | NOS3 (0.47) | NOS3NOS2LOXL2LOXADRB1 | |
| SCHEMBL810884 | 0.78 | NOS3 (0.61) | NOS3NOS2ADRB1MAPK1ADRB2 | |
| SCHEMBL607015 | 0.76 | NOS3 (0.59) | NOS3NOS2LOXL2IDO1ADRB1 | |
| SCHEMBL30328281 | 0.76 | LOXL2 (0.53) | NOS3NOS2LOXL2LOXNOTUM | |
| SCHEMBL2642373 | 0.76 | LOXL2 (0.53) | NOS3NOS2LOXL2LOXNOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109476600-A | Pyrithione, pharmaceutical compositions thereof and therapeutic use thereof for treating proliferative, inflammatory, neurodegenerative or immune-mediated diseases | 拜欧赛里克斯公司 | 2019-03-15 | — | — | CN | claimed |
| US-20170294605-A1 | Iridium complex, method for manufacturing same, and organic light-emitting devices using same | AAC Technologies Pte. Ltd. (SG) | 2017-10-12 | — | — | US | claimed |
| US-20170294606-A1 | Iridium complex, method for manufacturing same, and organic light-emitting devices using same | AAC Technologies Pte. Ltd. (SG) | 2017-10-12 | — | — | US | claimed |
| CN-105777812-A | Iridium complex, preparation method thereof and electroluminescent device applying iridium complex | 瑞声光电科技(常州)有限公司 | 2016-07-20 | — | — | CN | claimed |
| CN-105732724-A | Iridium complex, preparation method thereof and electroluminescent device applying same | 瑞声光电科技(常州)有限公司 | 2016-07-06 | — | — | CN | claimed |
| WO-2024061804-A1 | AN ELECTROLUMINESCENT DEVICE COMPRISING AN ANODE LAYER, A CATHODE LAYER, A FIRST EMISSION LAYER, A HOLE INJECTION LAYER AND A FIRST HOLE TRANSPORT LAYER THAT COMPRISES A COMPOUND CONTAINING A METAL | NOVALED GMBH (DE) | 2024-03-28 | — | — | WO | disclosed |
| WO-2023148215-A1 | 3,6-BIS(CYANOMETHYLIDENE)CYCLOHEXA-1,4-DIENE COMPOUNDS AND THEIR USE IN ORGANIC ELECTRONIC DEVICES | NOVALED GMBH (DE) | 2023-08-10 | — | — | WO | disclosed |
| EP-4223739-A1 | 3,6-BIS(CYANOMETHYLIDENE)CYCLOHEXA-1,4-DIENE COMPOUNDS AND THEIR USE IN ORGANIC ELECTRONIC DEVICES | Novaled GmbH (DE) | 2023-08-09 | — | — | EP | disclosed |
| WO-2022263530-A1 | (THI)OXAZOLINE PESTICIDES | ELANCO TIERGESUNDHEIT AG (US) | 2022-12-22 | — | — | WO | disclosed |
| US-20220389007-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) | 2022-12-08 | — | — | US | disclosed |
| CN-109476600-A | Pyrithione, pharmaceutical compositions thereof and therapeutic use thereof for treating proliferative, inflammatory, neurodegenerative or immune-mediated diseases | 拜欧赛里克斯公司 | 2019-03-15 | — | — | CN | disclosed |
| US-20170294606-A1 | Iridium complex, method for manufacturing same, and organic light-emitting devices using same | AAC Technologies Pte. Ltd. (SG) | 2017-10-12 | — | — | US | disclosed |
| CN-105263935-A | 6, 7-dihydropyrazolo [1,5-a ] pyrazin-4 (5H) -one compounds and their use as negative allosteric modulators of MGLUR2 receptors | JANSSEN PHARMACEUTICA NV | 2016-01-20 | — | — | CN | disclosed |
| EP-2531492-A1 | 1,2,4-TRIAZINE-4-AMINE DERIVATIVES | Heptares Therapeutics Limited (GB) | 2012-12-12 | — | — | EP | disclosed |
| WO-2011095625-A1 | 1,2,4-TRIAZINE-4-AMINE DERIVATIVES | HEPTARES THERAPEUTICS LIMITED (GB) | 2011-08-11 | — | — | WO | disclosed |
| US-5670656-A | Process for preparing pyrrolidinones | ZENECA LIMITED (GB) | 1997-09-23 | — | — | US | disclosed |
| US-4563529-A | VAPOR PHASE CATALYTIC FLUORINATION OF PICOLINES OR LUTIDINES | ISHIHARA SANGYO KAISHA LTD. (JP) | 1986-01-07 | — | — | US | disclosed |
| US-4474599-A | 1-(Pyridyl)-1H-1,2,3-triazole derivatives, and use as herbicidal agents | THE DOW CHEMICAL COMPANY (US) | 1984-10-02 | — | — | US | disclosed |
| EP-0042696-B1 | PROCESS FOR PRODUCING TRIFLUOROMETHYLPYRIDINES | ISHIHARA SANGYO KAISHA LTD. (JP) | 1983-11-16 | — | — | EP | disclosed |
| EP-0042696-A1 | Process for producing trifluoromethylpyridines | ISHIHARA SANGYO KAISHA LTD. (JP) | 1981-12-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220389007-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | EIF2AK2, POLR2E, POLR2H | NOS3 2529/4885NOS2 2271/4885LOXL2 4586/4885 |
| US-20170294605-A1 | Iridium complex, method for manufacturing same, and organic light-emitting devices using same | ORC3, ORMDL3, TYK2 | NOS3 3762/4885NOS2 3507/4885LOXL2 299/4885 |
| US-20170294606-A1 | Iridium complex, method for manufacturing same, and organic light-emitting devices using same | ODC1, ORC3, DDC | NOS3 3716/4885NOS2 3143/4885LOXL2 2269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.